Skip to main content
Fig. 1 | BMC Complementary and Alternative Medicine

Fig. 1

From: Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

Fig. 1

Effects of TSF on urinary L-FABP levels in microalbuminuria patients during the 24-week treatment period. Values presented as mean ± SE; *P = 0.004 and # P = 0.047 compared with the placebo group at the same time point. L-FABP = liver-type fatty acid binding protein

Back to article page
\